Your unrestricted view into eyecare conferences across the spectrum. Gain exclusive access to Ophthalmology Times Europe® expert-led conference coverage from major meetings throughout the year featuring articles, videos, and insights shared by prominent experts of the ophthalmic community
July 21st 2022, 7:18am
At ASRS 2022, Dr Sally Ong presented a talk entitled, “Vitrectomy vs Vitrectomy With Scleral Buckling in the Treatment of Giant Retinal Tear Related Retinal Detachments: International Multicentre Study.” Here she shares the biggest takeaways.
July 19th 2022, 7:18am
The American Society of Retina Specialists held its 40th Annual Meeting in New York, New York, United States, from 13-16 July, 2022. While data was presented for all topics in retina, new revelations in age-related macular degeneration, diabetic retinopathy, and diabetic macular oedema dominated the conversation.
July 16th 2022, 6:12pm
KALAHARI study update; novel surgical approaches for progressive retinal detachments; and a new risk is identified for CST fluctuations.
July 15th 2022, 7:00pm
Metformin may provide AMD protection; DAVIO presents positive 12-month results; TOWER study reveals new imaging index for AMD.
July 14th 2022, 8:30am
Topics spanned from faricimab in nAMD and DME; pediatric retinal detachment surgery; and the relationship between outer retinal integrity and subretinal fluid.
July 7th 2022, 6:24pm
The 40th annual Scientific Meeting of the American Society of Retina Specialists is scheduled for July 13-16, 2022, in New York City, New York, United States.
June 20th 2022, 7:32am
Dr Sally Tucker of Ora Europe walks through the clinical trial pathway, describing how Ora addresses complexities to make the path as efficient as possible.
June 14th 2022, 7:38am
Jeff Cleland, PhD, CEO of Ashvattha, discusses safety data for an at-home subcutaneous anti-VEGF injection option in development for the treatment of wet AMD and DMO.
June 12th 2022, 7:32am
Takeaway: there doesn't seem to be a specific dry eye phenotype that does better or worse.
June 11th 2022, 7:47am
The OpRegen trial is a cell therapy trial, looking to explore potential safety and efficacy for patients with advanced dry age-related macular degeneration (AMD).